Pharmacotherapeutics of SARS-CoV-2 Infections

The COVID-19 pandemic has affected more than 38 million people world-wide by person to person transmission of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Therapeutic and preventative strategies for SARS-CoV-2 remains a significant challenge. Within the past several months, effe...

Descripción completa

Detalles Bibliográficos
Autores principales: Kevadiya, Bhavesh D., Machhi, Jatin, Herskovitz, Jonathan, Oleynikov, Maxim D., Blomberg, Wilson R., Bajwa, Neha, Soni, Dhruvkumar, Das, Srijanee, Hasan, Mahmudul, Patel, Milankumar, Senan, Ahmed M., Gorantla, Santhi, McMillan, JoEllyn, Edagwa, Benson, Eisenberg, Robert, Gurumurthy, Channabasavaiah B., Reid, St Patrick M., Punyadeera, Chamindie, Chang, Linda, Gendelman, Howard E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2021
Materias:
Invited Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7785334/
https://www.ncbi.nlm.nih.gov/pubmed/33403500
http://dx.doi.org/10.1007/s11481-020-09968-x
Descripción
Sumario:The COVID-19 pandemic has affected more than 38 million people world-wide by person to person transmission of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Therapeutic and preventative strategies for SARS-CoV-2 remains a significant challenge. Within the past several months, effective treatment options have emerged and now include repurposed antivirals, corticosteroids and virus-specific antibodies. The latter has included convalescence plasma and monoclonal antibodies. Complete viral eradication will be achieved through an effective, safe and preventative vaccine. To now provide a comprehensive summary for each of the pharmacotherapeutics and preventative strategies being offered or soon to be developed for SARS-CoV-2. GRAPHICAL ABSTRACT: [Image: see text]

Ejemplares similares